Aslan Pharma raises US$34m in fresh funding
Add BT as a preferred source
Singapore
THE Republic's fledgling pharma ecosystem on Monday got a shot in the arm as biotech startup Aslan Pharmaceuticals announced it has raised US$34 million in Series C funding led by Accuron Technologies, a tech subsidiary of Temasek Holdings.
The proceeds, said Aslan, will be used to further accelerate clinical development of its pipeline of four novel therapeutic agents, all of which have the potential to treat tumour types "prevalent in Asia", such as gastric, bile duct and breast cancers.
TRENDING NOW
Singapore at 61: How we can ensure opportunity, security and ownership for the next generation
With tech for fact-checking to cancer care, Singapore startups aim beyond home
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
Why Asean matters more than ever to the UK and Singapore
